ライフサイエンスコーパス: mouse model

1 hemolytic anemia, and tumor development in a mouse model.

2 otoreceptors of a heterozygous Opa1 knockout mouse model.

3 icacy using in vivo MMTV-neu transplantation mouse model.

4 or stress experience and fit our established mouse model.

5 isruption under the aegis of p53siRNA in the mouse model.

6 nt and maintenance of fHC in mammals using a mouse model.

7 alleviates motor symptoms in a parkinsonian mouse model.

8 nst cashew-induced anaphylaxis in a relevant mouse model.

9 bol-13-acetate two-stage skin carcinogenesis mouse model.

10 osition 7 in the seed region was active in a mouse model.

11 rmacokinetic parameters and potency in a CDI mouse model.

12 the mammalian brain, we generated a knockout mouse model.

13 ntal bone and root loss are observed in this mouse model.

14 LC) number and function in a Dock8-deficient mouse model.

15 in penetrant TORKi showing efficacy in a TSC mouse model.

16 epleted from POMC neurons using an inducible mouse model.

17 t tumour suppressor in a SHH medulloblastoma mouse model.

18 noculation via the tail vein in a bacteremia mouse model.

19 cute colitis in a humanized IL-26 transgenic mouse model.

20 the xenograft human hepatocellular carcinoma mouse model.

21 rain homogenates from an Alzheimer's disease mouse model.

22 ches in the oxygen-induced retinopathy (OIR) mouse model.

23 adenomatous polyposis coli (APC(Delta14/+)) mouse model.

24 iruses had increased lethality in the DBA2/J mouse model.

25 sual mapping defects in a well-characterized mouse model.

26 n of a mutant Braf;Pten loss-driven melanoma mouse model.

27 tion and pathogenesis in an in vivo suckling mouse model.

28 RC01-N using a highly reproducible humanized mouse model.

29 vicovaginal HPV16 pseudovirus infection in a mouse model.

30 limited tumor growth in a tumor implantation mouse model.

31 he hepatic conditional beta-catenin knockout mouse model.

32 d spleen and is lethal in a hemolytic anemia mouse model.

33 tes SCLC progression in an Rb1/Trp53-deleted mouse model.

34 using human keratinocyte tissue culture and mouse models.

35 derived GBM xenografts in both zebrafish and mouse models.

36 macrophages in both in vitro and in vivo GBM mouse models.

37 ld-type mice and tau knock-out and P301L tau mouse models.

38 cular importance to cancer researchers using mouse models.

39 these agents in vivo using wild-type and mdx mouse models.

40 tracing, immunohistochemistry, and reporter mouse models.

41 cells in immunodeficient and immunocompetent mouse models.

42 mes, which promotes tumorigenesis in various mouse models.

43 or a single hippocampus from Lafora disease mouse models.

44 ements or neuropathological features in DYT1 mouse models.

45 loid load and improve cognitive functions in mouse models.

46 h as well as metastasis in the tumor-bearing mouse models.

47 ly attenuates HCC tumorigenesis in xenograft mouse models.

48 prostate tumorigenesis using newly generated mouse models.

49 for the development of genetically modified mouse models.

50 mmune evasion and promoting tumour growth in mouse models.

51 SG7 slows tumor growth in multiple syngeneic mouse models.

52 ntry and spread and is protective in vivo in mouse models.

53 ocesses at the molecular level in convenient mouse models.

54 e does not appear to benefit SRS patients or mouse models.

55 ardial infarction (MI)-induced heart failure mouse models.

56 cer patient data, cell lines, and orthotopic mouse models.

57 formation of amyloid plaques in a transgenic mouse model (5xFAD) of early amyloid deposition.

58 TAM depletion-repletion experiments in a 4T1 mouse model additionally revealed that anti-inflammatory

59 evant myocardial ischemia reperfusion injury mouse model after i.v. injection confirms the ability of

60 both the c-Jun/JunB and imiquimod psoriasis mouse model allowed us to study the therapeutic mechanis

61 A knockout mouse model allows dissociation of the coordination betw

62 Preclinical studies using an in vivo mouse model also demonstrated that combining Enz plus ol

63 matoid arthritis FDA-approved drug) in a CDI mouse model and establish an adequate dosage for treatme

64 as shown efficacy in the retina light damage mouse model and in humans for multiple sclerosis.

65 ctivity of compound 42 in a TNF-induced IL-6 mouse model and in vivo activity in a collagen antibody-

66 Using CRISPR-generated mouse models and biochemical assays, we demonstrate the

67 ore the mechanisms behind these functions in mouse models and human cells, including interactions wit

68 nscriptional cofactor HOPX is upregulated in mouse models and in human YAP1-fusion induced ependymoma

69 some cognitive and behavioral outcomes in DS mouse models and in humans with Ts21.

70 es and high fat diet-induced type 2 diabetes mouse models and liver-specific Prmt1 deficiency drastic

71 With the development of knockout mouse models and molecular inhibitors unique to necropto

72 n-regulated in the visceral fat of two obese mouse models and obese patients.

73 graphy (ARG) studies in brain slices from HD mouse models and postmortem human HD samples.

74 ere consistent with observations reported in mouse models and subjects with FXS.

75 The combination of conditional knockout mouse models and viral vector-mediated autophagy-modulat

76 an be successfully examined in the humanized mouse model, and experimentally validate the predicted f

77 tion was critical for AD progression in this mouse model, and that disease progression could be ameli

78 ted inhibition of IL2RA in human cell lines, mouse models, and primary patient samples, we investigat

79 eta PET and TSPO PET in 4 investigated Abeta mouse models (APP/PS1: R = 0.593, P = 0.001; PS2APP: R =

80 In contrast to cell culture systems, mouse models are highly favored for evaluating tumor pro

81 Upon testing in a CDI mouse model, auranofin at low clinically achievable dose

82 In in vivo studies using a syngeneic mouse model bearing orthotopically injected 4T1 cells, C

83 scriptional profiling in an adult-onset Pkd2 mouse model before cysts formed revealed significant dif

84 aphy fractioned protein samples from 3xTg-AD mouse model brain homogenates.

85 on has been demonstrated in MFS patients and mouse models, but little is known about the intrinsic ef

86 s intestinal tumorigenesis in the Apc(Min/+) mouse model by inhibiting Wnt/beta-catenin signaling.

87 Here, we have created a mouse model by using CRISPR technology to mutate a singl

88 r, wild-type mice and all existing humanized mouse models cannot be used to test the efficacy of vacc

89 In humanized mouse models, CAR-Ms were further shown to induce a pro-

90 We utilized a mouse model carrying a knockout of the mitochondrial fus

91 Evidence from mouse models correlates AM function with their embryonic

92 Reasoning that mouse models could similarly offer important insights in

93 s in pediatric T-ALL and generated a RoLoRiG mouse model crossed to Mx1CRE to determine the consequen

94 ur studies in an immunocompetent preclinical mouse model demonstrate TAMs can have a functional role

95 Using this mouse model denoted knock-in alpha2 (KI alpha2), our ele

96 The mouse models described here may be useful for further me

97 In contrast, treatment with pure EGCG in DS mouse models did not improve neurobehavioral phenotypes.

98 we reveal the cause of this deafness using a mouse model engineered with a noncoding intronic 10 bp d

99 urthermore, Tet2 deletion-PyMT breast cancer mouse model exhibits enhanced mammary tumor development

100 Research, Park and colleagues describe a new mouse model featuring a single amino acid substitution i

101 vivo, we developed a conditional transgenic mouse model (Flpo/Frt system) expressing bioactive TGFbe

102 Ile) variant detected in an mARHL case, as a mouse model for a monogenic form of presbycusis.

103 ere, we present a new genetically engineered mouse model for non-AR-driven prostate cancer that cente

104 Using a transgenic mouse model for the sonic hedgehog (Shh) subgroup of med

105 ew models has the potential to revolutionize mouse modeling for melanoma.See related article by Bok e

106 atient-derived xenografts (PDX) are tumor-in-mouse models for cancer.

107 However, genetic evidence in mouse models for prostate cancer to support the crucial

108 diverse NUP98-fusion proteins, we developed mouse models for regulatable expression of NUP98/NSD1, N

109 en hinders the use of genetically engineered mouse models (GEMM) in cancer research.

110 Genetically engineered mouse models (GEMMs) of cancer have proven to be of grea

111 ed ex vivo from an autochthonous lung cancer mouse model had lower mitochondrial membrane potential a

112 although heterologous expression systems and mouse models have demonstrated altered sodium current pr

113 sgenes and additional mutations in humanized mouse models, have expanded our opportunities to replica

114 iew progress and challenges in the use of AD mouse models, highlight emerging scientific innovations

115 In a mouse model in which both pathways are activated in stem

116 ity in PDAC progression, we generated a PDAC mouse model in which CAF plasticity is modulated by gene

117 Using a mouse model in which endothelial Dhh is inducibly delete

118 We established a mouse model in which repeated systemic vincristine treat

119 used a Bardet-Biedl syndrome type 17 (BBS17) mouse model, in which the gene-trap that suppresses Bbs1

120 ence and infectivity assays using insect and mouse models indicate roles in pathogenicity for 31 phos

121 nificantly and reversed immunosuppression in mouse models, indicating its potential as an in vivo too

122 In the pristane-induced lupus mouse model, inhibition of IRAK4 reduced the expression

123 Here, we describe a mouse model intended to reproduce hereditary PPGL throug

124 A major problem with such mouse models is that bnAb expression often hinders B cel

125 In genetic Apc-mutant mouse models, loss of Prox1 promoted the growth of desmo

126 n a humanized alpha-synuclein overexpressing mouse model; mice treated at 12 months of age when motor

127 diet can rescue synaptic plasticity in this mouse model of AD (P = 0.007 to untreated APP/PS1).

128 s in brain, heart, and liver proteins from a mouse model of AD.

129 1 T MRI scanner using a transgenic APP/PSEN1 mouse model of Alzheimer's disease.

130 that shows efficacy in reducing disease in a mouse model of atherosclerosis.

131 abnormalities and mTORC1 hyperactivity in a mouse model of Birt-Hogg-Dube syndrome.

132 histogram-based analysis was performed in a mouse model of bleomycin (BLM)-induced pulmonary fibrosi

133 On the syngeneic mouse model of breast cancer, the iron-crosslinked Rosos

134 ped method was demonstrated in an orthotopic mouse model of breast cancer.

135 . pestis with neutrophils in the dermis in a mouse model of bubonic plague.

136 In the current study, using a mouse model of CAC, we show that the LRP5/6-beta-catenin

137 ons and after deletion of Pdcd10 (Ccm3) in a mouse model of CCM.

138 -S in a dextran sulfate sodium (DSS)-induced mouse model of colitis.

139 human sIgA before intranasal challenge in a mouse model of colonization.

140 vel high-density EEG electrode arrays in the mouse model of CSR where mice underwent 18-h sleep depri

141 issue of the JCI, Auguste et al. generate a mouse model of DCM in which they delete Lmna in cardiomy

142 ve undergone chronic social defeat stress, a mouse model of depression, at both the level of synaptic

143 the chronic unpredictable mild stress (CUMS) mouse model of depression.

144 We generated a symptomatic mouse model of DMD carriers via injection of mdx (murine

145 , we genetically ablated miR-133b in the mdx mouse model of DMD.

146 ovement of behavioral deficits in the Ts65Dn mouse model of Down syndrome (DS), translation to human

147 tures of mouse glial cells and in vivo, in a mouse model of EcoHIV-associated brain inflammation, as

148 cytokine, extends lifespan in the SOD1-G93A mouse model of familial ALS.

149 after injury, and reverses vision loss in a mouse model of glaucoma and in aged mice.

150 Here, using a native mouse model of glioblastoma, we develop a high-throughpu

151 ld improve behavioral phenotypes in the R6/2 mouse model of HD and modulate HD-associated changes in

152 vestigated the role of PAG1 in a preclinical mouse model of house dust mite (HDM)-induced allergic se

153 time points and brain regions in a relevant mouse model of human tauopathy, the hTau mice, in relati

154 cytometry were used to characterize a novel mouse model of hyperuricemia and chronic UA crystal neph

155 is effective at lowering bacterial load in a mouse model of infection.

156 cell-mediated tissue injury as observed in a mouse model of intestinal graft-versus-host disease (GVH

157 insights into the requirement for Runx1 in a mouse model of inv(16) acute myeloid leukemia (AML).

158 dings in LF patients were recapitulated in a mouse model of LASV infection, in which mucosal exposure

159 tin signalling on the disease phenotype in a mouse model of LGMD R1 (CAPN3 knockout mouse-C3KO) was s

160 hiculization was also evaluated in vivo in a mouse model of lipopolysaccharide (LPS)-induced acute lu

161 mors in a highly aggressive, immunocompetent mouse model of lung adenocarcinoma improves long-term su

162 t not tumor progression, in an autochthonous mouse model of lung cancer.

163 c response during sickness and recovery in a mouse model of malaria.

164 rain barrier dysfunction, and mortality in a mouse model of malaria.

165 Here we utilized a mouse model of maternal immune activation (MIA) with the

166 Here, we used a mouse model of maternal obesity to investigate the impor

167 lex, a major downstream target of RAC1, in a mouse model of melanoma driven by BRAF(V600E);PTEN loss.

168 In a mouse model of metastatic ovarian cancer, fluorescently

169 Using a mouse model of neonatal tendon regeneration, we identifi

170 In a genetically engineered mouse model of non-small cell lung cancer driven by K-Ra

171 ding ceramides, are selectively reduced in a mouse model of obesity.

172 om patients with OS and from the Rag2(R229Q) mouse model of OS abundantly express the skin homing rec

173 y to GPe parvalbumin-expressing neurons in a mouse model of Parkinson's disease, we discovered eviden

174 arker gammaH2AX in PanIN-3s in an engineered mouse model of PDAC, to facilitate early detection of PD

175 r agonistic autoantibody (AT(1) -AA)-induced mouse model of PE.

176 In a mouse model of persistent lymphocytic choriomeningitis v

177 To address this gap, we adapted an infant mouse model of pneumococcal colonization and transmissio

178 ly monitored the competence development in a mouse model of pneumonia-derived sepsis.

179 GDH inhibition were studied in the bleomycin mouse model of pulmonary fibrosis.

180 ed the effects of aberrant neurogenesis in a mouse model of repeated mild traumatic brain injury (rmT

181 nels in light-insensitive retinal cones in a mouse model of retinal degeneration.

182 We addressed this issue in an established mouse model of Retinitis Pigmentosa caused by the P23H m

183 we examined the role of Wnt6 in MeCP2 T158A mouse model of RTT.

184 n the meningeal lymphatics are depleted in a mouse model of SAH, the degree of erythrocyte aggregatio

185 ial for the formation of primary cilia, in a mouse model of SCLC induced by conditional deletion of b

186 lergen-induced Th2 inflammation and AHR in a mouse model of severe steroid resistant asthma, potentia

187 elial cells (MECs) from lacrimal glands of a mouse model of Sjogren syndrome.

188 nflammasome was confirmed in an experimental mouse model of stroke.

189 re to Delta9-tetrahydrocannabinol (THC) in a mouse model of surgically-induced endometriosis.

190 ional program in a cell-specific manner in a mouse model of synpolydactyly.

191 we assessed their therapeutic activity in a mouse model of T cell-mediated autoimmunity that mimics

192 etic humanized NOD-scidIL2Rgamma(null) (NSG) mouse model of T-cell-mediated human islet allograft rej

193 islet-infiltrating B lymphocytes in the NOD mouse model of T1D produce Abs directed against the neur

194 Using the well-established mouse model of TB, our new data provide evidence that th

195 We explore mechanisms by generating a mouse model of the orthologous Q140K Abcg2 variant and f

196 Here we use a mouse model of trauma-induced heterotopic ossification (

197 no et al. defines how genetic variation in a mouse model of type 1 diabetes mellitus (T1DM) affects l

198 te low-avidity autoreactive cells in the NOD mouse model of type 1 diabetes.

199 n impaired neurovascular function in several mouse models of AD, including the J20-hAPP mouse.

200 arameters and promotes beta-cell function in mouse models of beta-cell failure acting as a growth fac

201 re, we use genetically engineered orthotopic mouse models of breast cancer to show that while depleti

202 orable in vivo biodistribution properties in mouse models of CAIX-positive clear cell renal cell carc

203 ufficient to induce phenotypes identified in mouse models of cancer cachexia, including muscle fiber

204 -PD1 therapy in suppressing tumour growth in mouse models of cancer.

205 Current mouse models of CCHFV infection reliably succumb to viru

206 Mouse models of cervical cancer were used to evaluate th

207 ypothalamic inflammation and its sequelae in mouse models of diabetes.

208 nsor for multiplex optical urinalysis in the mouse models of drug-induced acute kidney injury (AKI) a

209 Mouse models of DS, involving trisomy of all or part of

210 Here, we use human and mouse models of EEC deficiency to identify an unapprecia

211 ired resistance to osimertinib in transgenic mouse models of EGFR(L858R) -induced lung adenocarcinoma

212 patient-derived orthotopic xenograft (PDOX) mouse models of GBM.

213 ic studies in in vitro and in vivo human and mouse models of HGG.

214 duces enteric nervous system regeneration in mouse models of HSCR.

215 Mouse models of human cancer have transformed our abilit

216 In vivo, m-RCT was evaluated in mouse models of hypercholesterolemia that were naturally

217 Mouse models of infection have demonstrated a role for M

218 NF) correlate with neuromuscular deficits in mouse models of Kennedy's disease (KD), suggesting that

219 es and circulating tumor cells (CTCs) in two mouse models of mammary cancer: genetically modified MMT

220 e evaluated the performance of the probes in mouse models of mammary tumours and of metastatic lung c

221 ing inflammation promotes social behavior in mouse models of neurodevelopmental disorders.

222 n of liver necroinflammation and fibrosis in mouse models of non-alcoholic fatty liver disease and ad

223 iscuss approaches that have shown effects in mouse models of obesity and metabolic disorders, and how

224 d in the motor deficits of dopamine-depleted mouse models of Parkinson's disease, where cell type-spe

225 Two mouse models of polymerase exonuclease deficiency shed l

226 Mouse models of prenatal immune activation often involve

227 ng proteomic and bioinformatic approaches in mouse models of protease-induced plaque rupture and in r

228 In mouse models of pulmonary metastases, MDSCs are key fact

229 ated in metastases-associated fibroblasts in mouse models of spontaneous breast cancer metastasis and

230 In mouse models of SS, inhibition of BMP6 signaling reduced

231 her-to-child effect is reproduced in several mouse models of stress, which have been crucial in devel

232 s glucose homeostasis in dietary and genetic mouse models of T2D.

233 disruption of endogenous genes in transgenic mouse models of tauopathy make it difficult to draw defi

234 enuates heme-induced microvascular stasis in mouse models of VOC.

235 mmonly used ZIKV strains, in two widely used mouse models of ZIKV pathogenesis.

236 In the MMTV-Delta16HER2 transgenic mouse model, oncogene transformation resulted in a timel

237 ons were replicated in the Q175 Htt knock-in mouse model (p = 6.0 x 10(-8)) and in the transgenic she

238 The developed mouse model permits enhancement of gene expression by us

239 tify similarities between human diseases and mouse models produced by the International Mouse Phenoty

240 dysregulated glucose homeostasis in multiple mouse models, prolonging the healthy life span.

241 The COL1A2-CCN1 mouse model provides a novel tool for understanding and

242 PXN silencing in ovarian cancer mouse models reduced angiogenesis, tumor growth, and met

243 6-F10 melanoma and MC38 colorectal carcinoma mouse models, reprogramming nanoparticles in combination

244 Knockout of Gdf6 in a mouse model resulted in cochlear aplasia, closely resemb

245 reverse genetics and assays with Ifnar (-/-) mouse models revealed that while the SFTSV-A46 mutant re

246 ion in the KRAS mutation-related lung cancer mouse models revealed the suppressive effect of PIERCE1

247 mpal synaptic plasticity in the heterozygous mouse model sheds light on the pathophysiology of altere

248 nanoparticles to the neuroblastoma xenograft mouse model showed around 15-20% ITCH silencing 48 hours

249 The PTHS mouse models showed cell-autonomous reductions in OL num

250 Turning to a mouse model, Smoc2-GFP reporter expression indicates SMO

251 Observations in a mouse model suggest that a mutation in the WFS1 gene may

252 cessibility, ameliorated light damage in our mouse model, supporting a causal link between decreased

253 Studies in classical mouse model systems have provided evidence that balancin

254 Herein, we generated a mouse model that allow for activation of NF-kappaB speci

255 Here, we describe a novel mouse model that allows emicizumab function to be examin

256 In this study, we use a mouse model that applies an improved genetic definition

257 eriod in an intrahippocampal chemoconvulsant mouse model that develops epilepsy.

258 follow-up lipid analysis was undertaken in a mouse model that has an insulin-resistant heart and is s

259 ed at establishing a novel collection of HCC mouse models that captured human HCC diversity.

260 These findings demonstrate the utility of mouse models that integrate genomic alterations with rel

261 We also show in mouse models that tonic signalling leads to superior mor

262 e an overview of the studies in experimental mouse models that try to address this question.

263 y established mammary specific Tet2 deletion mouse model, the data reveals that TET2 plays a pivotal

264 bolic analyses in ROCK2(+/-) and ROCK2(+/KD) mouse models, the latter harboring an allele with a kina

265 n this study, we used a cord blood-humanized mouse model to compare the phenotypes of an EBNA3A hypom

266 Here we used a novel transgenic mouse model to compare the spatial distribution of zonat

267 We created a Ewsr1 conditional knockout mouse model to deplete EWSR1 before the onset of meiosis

268 e was to describe the glial response in this mouse model to educate future experimentation.

269 ed the unilateral ureteral obstruction (UUO) mouse model to investigate the expression and mechanisms

270 In this study, we use a reporter mouse model to permanently "time stamp" NK cells and typ

271 this study, we take advantage of a humanized-mouse model to probe the contribution of APOBEC3 mutagen

272 study used a cardiac-specific VCP transgenic mouse model to understand the transcriptomic alterations

273 Here we used organoid and mouse models to determine the drivers of altered cholest

274 uman chromosome 14q32 has enabled the use of mouse models to elucidate imprinting mechanisms and deci

275 We utilized knockin and transgenic mouse models to evaluate the structural, functional and

276 Here, we use multiple mouse models to investigate in vivo consequences.

277 We used multiple mouse models to investigate the mechanisms of NMJ reinne

278 employ cellular models, primary neurons and mouse models to investigate the potential differential r

279 In this study, we use genetic mouse models to show that loss of AlphaMPKalpha1 in B ce

280 Using type 1 diabetic (T1DM) mouse models together with cultured Schwann cells (SCs)

281 In this mouse model, treatment with corticosteroid allows for in

282 Heterotopic tracheal transplantation (HTT) mouse model was used to evaluate the effect of local GNP

283 re overload-induced cardiac hypertrophy in a mouse model, we characterized the spatiotemporal interpl

284 In this study, using a knockout mouse model, we show that the transcription factor hypox

285 Using the corresponding Plp1 transgenic mouse model, we then tested the capacity of transplanted

286 o patient samples and genetically engineered mouse models, we developed organoid systems from primary

287 ex coupled with conditional genetic knockout mouse models, we further discovered that the E3 ubiquiti

288 Using acute myeloid leukemia (AML) mouse models, we show AML blasts release inflammatory me

289 The established HCC mouse models were characterized at histopathological, im

290 Novel mouse models were generated to further investigate the f

291 ic PDE9a inhibition, 2 diastolic dysfunction mouse models were studied: (1) TAC-deoxycorticosterone a

292 ostasis, we generated genetically engineered mouse models where we can conditionally delete Stk11 and

293 These newly identified markers and mouse models will be an invaluable resource for decipher

294 190A is a tumor suppressor using a xenograft mouse model with carcinoma cells harboring defined ARHGA

295 The preclinical study using an in vivo mouse model with orthotopic xenografts of HCC cells conf

296 brain circuits in vivo, here, we generated a mouse model with primate-lineage-specific isoforms of C4

297 a-Gal(null) is the first available humanized mouse model with such features.

298 s second-site mutation in vivo, we created a mouse model with the corresponding V558Delta;V653A Kit d

299 Using a mouse model with two reporter genes, we observed that, w

300 Using mouse models with genetic loss of CB1R or GLP-1R, we dem